B
ADPT icon

Braidwell’s Adaptive Biotechnologies ADPT Stock Holding History

Braidwell’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-311,991
Closed -$5.07M – 89
2025
Q4 		$5.07M Sell
311,991
-424,023
-58% -$6.92M 0.16% 69
2025
Q3 		$11M Sell
736,014
-3,127,093
-81% -$38.1M 0.33% 64
2025
Q2 		$45M Sell
3,863,107
-940,687
-20% -$8.54M 1.54% 24
2025
Q1 		$35.7M Buy
+4,803,794
New +$36.9M 1.25% 34
2024
Q2 		– Sell
-1,357,490
Closed -$4.36M – 76
2024
Q1 		$4.36M Hold
1,357,490
– – 0.14% 69
2023
Q4 		$6.65M Buy
1,357,490
+389,800
+40% +$1.78M 0.24% 67
2023
Q3 		$5.27M Buy
967,690
+319,239
+49% +$2.11M 0.17% 85
2023
Q2 		$4.35M Hold
648,451
– – 0.14% 78
2023
Q1 		$5.73M Buy
+648,451
New +$5.72M 0.19% 73

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Braidwell's ADPT Position: Q1 2026 in Review

Braidwell sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 311,991 shares — an estimated $5.07M sold.

Braidwell first reported a position in ADPT in Q1 2023 and held it in 9 quarters. The position peaked at $45M in Q2 2025. 298 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Braidwell reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
  • Braidwell sold 311,991 Adaptive Biotechnologies shares in Q1 2026, an estimated $5.07M.
  • Braidwell first reported a position in Adaptive Biotechnologies in Q1 2023 and held it in 9 quarters.
  • Braidwell's Adaptive Biotechnologies position peaked at $45M in Q2 2025.
  • 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.